Test Price
6,000 AED✅ Home Collection Available
Oncomine Focus Panel in the UAE – Targeted NGS for Cancer Mutation Profiling
Executive Summary & Core Metrics
DHA‑Compliant Diagnostic Sensitivity: 99.9% via ISO 9001:2015 Accredited NGS Processing.
- ✓ Premium Logistics: Secure Medical Courier Solid Tissue Specimen Retrieval – available daily from 8 AM to 11 PM.
- ✓ Clinical Guidance: Telephonic Post-Test Result Interpretation by a Consultant Diagnostic Radiology (DHA License No. 61713011).
- ✓ Insurance: Direct Billing Verification via WhatsApp at +971 54 548 8731.
Test Overview & Methodology
The Oncomine Focus Panel is a next‑generation sequencing (NGS) assay that examines tumor tissue for actionable genetic mutations across 52 oncogenes – enabling precise targeted therapy selection. In the UAE, this ISO‑certified test integrates DHA‑mandated safety protocols, guaranteeing clinically validated results within 2–3 weeks. The methodology employs a targeted amplicon‑based approach on the Thermo Fisher Oncomine™ platform, delivering high sensitivity and specificity for clinically relevant variants.
| Feature | Our Test (ISO 9001:2015) | Closest Alternative |
|---|---|---|
| Analytical Method | Targeted NGS (Thermo Fisher Oncomine™) | Single‑Gene PCR / FISH |
| Genes Covered | 52 clinically relevant oncogenes (ALK, EGFR, BRAF, KRAS, etc.) | 1–3 genes per assay |
| Turnaround Time | 2‑3 weeks (fixed) | 7–14 days for limited targets |
| Regulatory Adherence | DHA‑Licensed Facility, PDPL‑Compliant | Variable internal lab accreditation |
Physician Insight & Safety Protocols
“As a DHA‑licensed practitioner, I remind you that the Oncomine Focus Panel results must always be interpreted alongside the patient’s full clinical picture, imaging, and pathology—never in isolation. The data guide precision oncology but do not replace clinical judgment.”
M. Mr. Prabhakar Reddy Kalathoor — Specialist Diagnostic Radiology, DHA License No. 61713011
1. Safety Advisory & Precautions
Do not discontinue any prescribed oncology treatment or targeted therapy without consulting your doctor. This test informs therapeutic decisions but never overrides approved clinical regimens. Always follow up with your oncologist for medication adjustments.
2. Safety Exclusion Criteria & Emergency Red Flags
- Inadequate tumor tissue: Tumor content <10% (NGS sensitivity requires sufficient neoplastic DNA).
- Formalin-fixed paraffin-embedded (FFPE) specimen older than 5 years may yield degraded nucleic acids.
- Pregnancy or imminent surgery: Test not indicated for non‑oncologic clearance; consult your oncologist.
- Travel‑related testing: This panel is not a screening tool for travel; a doctor’s prescription is mandatory, and this indication is excluded.
- Emergency signs: If the patient experiences severe bleeding at the biopsy site, uncontrolled pain, or signs of infection, seek immediate hospital care—do not rely solely on this test result.
Patient FAQ & Clinical Guidance
1. What exactly does the Oncomine Focus Panel detect, and how does it help my treatment?
This targeted NGS panel identifies 52 cancer‑driving gene mutations in your tumor, directly matching your malignancy to FDA‑approved or guideline‑recommended targeted therapies. The report pinpoints drugs that are likely to work, spares you from ineffective treatments, and often opens access to clinical trials — converting molecular data into a personalized cancer roadmap.
2. How is the tumor tissue sample collected and transported for this test?
The sample is an archival tumor specimen (FFPE block or fresh biopsy) obtained at a hospital or clinic by the treating physician. Our DHA‑licensed courier service retrieves the specimen under strict cold‑chain conditions using a validated transport container, ensuring DNA integrity throughout transit. No home phlebotomy is required for this test.
3. Can I undergo this test without a doctor's prescription in the UAE?
No — UAE Federal Law (Federal Decree-Law No. 45 of 2021 on Personal Data Protection and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields) mandates a valid physician’s prescription for all advanced genomic tests. The prescription must be from a licensed practitioner, and this test is not approved for stand‑alone screening, travel clearance, or pregnancy‑related requests.
UAE Regulatory & Data Privacy Adherence
Our testing process fully complies with:
- Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) – ensuring patient data confidentiality and secure handling of genetic information.
- Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields – governing safe electronic health data transfer and storage.
- Federal Decree-Law No. 4 of 2016 on Medical Liability – establishing clinical responsibility and patient consent protocols.
- DHA Licensing and inspection standards for facilities handling tumor specimens and genetic testing.
This regulatory framework guarantees that your results are processed, stored, and shared with the highest legal and ethical standards.
Clinical & Logistical Metadata
| Test Name | Oncomine Focus Panel |
| Price (AED) | 6,000 |
| Turnaround Time | 2–3 weeks |
| Sample Type / Matrix | Tumor Tissue (FFPE block or fresh biopsy) |
| Methodology Used | Targeted Next-Generation Sequencing (NGS) – Thermo Fisher Oncomine™ |
| ICD-10-CM Code | C80.1 |
| LOINC Code | 77755-9 |
| DHA Facility License & Laboratory Address | DHA License No. 1143, Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | Corporate Lab: DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians